Avanos Medical (AVNS) Expected to Announce Earnings on Tuesday
Avanos Medical (AVNS) is expected to announce its Q4 2025 earnings before market open on Tuesday, February 24, 2026, with analysts projecting EPS of $0.24 and revenue of $174.7 million. The stock traded up 1.4% to $15.11, showing significant institutional ownership and mixed analyst ratings. Key financial metrics include a market cap of $701.17 million, a P/E ratio of -1.48, and a 12-month trading range of $9.30-$16.75.
Avanos Medical to Host Q4 2025 Financial Results Conference Call
Avanos Medical will host a conference call on February 24, 2026, at 9 a.m. ET to discuss its fourth quarter and full year 2025 financial results. CEO Dave Pacitti and CFO Scott Galovan will lead the call, which aims to enhance investor understanding and bolster market confidence. Investors can access the call via a registration link, designated phone numbers, or webcast, with a replay available for one week.
Thrivent Financial for Lutherans Has $1.78 Million Stake in Avanos Medical, Inc. $AVNS
Thrivent Financial for Lutherans significantly increased its stake in Avanos Medical, Inc. by 352.2% in the third quarter, bringing its total holdings to 153,764 shares valued at approximately $1.78 million. Other institutional investors also adjusted their positions in AVNS, which currently has a market cap of $702.4 million and a consensus analyst rating of "Reduce." This increase in institutional ownership occurs despite recent insider selling and mixed analyst sentiments.
Avanos Medical, Inc. (NYSE:AVNS) Held Back By Insufficient Growth Even After Shares Climb 26%
Avanos Medical (NYSE:AVNS) shares recently surged 26%, yet the company's price-to-sales (P/S) ratio of 1x remains low compared to the Medical Equipment industry average. This low P/S ratio is attributed to the company's sluggish revenue growth, which has lagged behind competitors, with analyst forecasts predicting only 0.9% growth next year versus 52% for the industry. Despite the recent stock increase, the insufficient growth outlook continues to deter investors from valuing the stock higher.
How (AVNS) Movements Inform Risk Allocation Models
This article analyzes Avanos Medical Inc. (NASDAQ: AVNS) using AI models to inform risk allocation. It highlights a strong near- and mid-term sentiment, a weak long-term outlook with elevated downside risk, and outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profiles. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Diamond Hill Capital Management Inc. Increases Holdings in Avanos Medical, Inc. $AVNS
Diamond Hill Capital Management Inc. significantly increased its stake in Avanos Medical, Inc. by 26.0% during the third quarter, now owning 434,661 shares valued at approximately $5.03 million. Other institutional investors also adjusted their positions, and despite some analyst upgrades, MarketBeat's consensus rating for Avanos Medical remains "Reduce." Meanwhile, an insider, SVP Kerr Holbrook, sold 15,000 shares, decreasing their ownership by over 15%.
Avanos Medical stock outlook detailed as Citizens reiterates Market Perform rating
Citizens has reiterated its "Market Perform" rating on Avanos Medical (NYSE:AVNS), citing the company's strategic repositioning and leadership change. With Dave Pacitti as CEO since April 2025, Avanos Medical aims for $1 billion in revenue by 2030, supported by strong free cash flow and recent positive financial results, including an earnings beat and a co-marketing agreement with Siemens Healthineers.
CMS Maintains NOPAIN Act Eligibility for ON‑Q* and AmbIT* Infusion Pumps; Adds Game Ready* in 2026
Avanos Medical announced that the Centers for Medicare and Medicaid Services (CMS) upheld the NOPAIN Act eligibility for its ON‑Q* and AmbIT* infusion pumps and added the Game Ready* GRPro 2.1 system for 2026. This act ensures separate Medicare payment for qualifying non-opioid pain management devices in Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings from 2025 to 2027. The decision expands patient access to non-opioid alternatives for post-surgical pain and supports the reduction of opioid dependence.
Medicare to pay up to $2,008.72 for Avanos non-opioid pain devices
Avanos (NYSE: AVNS) announced that the CMS 2026 OPPS/ASC Final Rule maintains separate Medicare payment under the NOPAIN Act for its ON-Q and ambIT infusion pumps and adds the Game Ready GRPro 2.1 system, effective January 1, 2026. The CMS has assigned unique HCPCS codes and published payment limits of $2,008.72 for ON-Q and ambIT, and $1,997.16 for Game Ready when medically necessary and used with a covered surgical procedure. This decision supports expanded patient access to non-opioid pain management alternatives.
Avanos Medical (NYSE:AVNS) Raised to "Hold" at Zacks Research
Zacks Research has upgraded Avanos Medical (NYSE:AVNS) from a "strong sell" to a "hold" rating, despite a mixed analyst landscape where other firms like Weiss issued a "sell" and Wall Street Zen a "strong-buy." The medical technology company recently surpassed quarterly earnings and revenue expectations ($0.22 EPS vs. $0.12 expected; $177.8M vs. $164.5M) but reported a negative net margin and provided FY2025 EPS guidance between $0.85 and $0.95. The stock currently has a consensus "Reduce" rating among analysts.
Siemens Healthineers and Avanos team up to support outpatient pain care
Siemens Healthineers and Avanos Medical have formed a co-marketing agreement to advance outpatient and interventional pain management. This partnership will integrate Siemens’ mobile imaging systems with Avanos’ radiofrequency ablation (RFA) devices, targeting ambulatory surgery centers, hospitals, and interventional pain clinics. The collaboration aims to enhance workflow efficiency and procedural precision as pain care continues to shift away from traditional inpatient settings, initially focusing on the U.S. market.
Avanos Medical, Inc. (AVNS) Stock Analysis: Navigating Growth Potential Amidst Valuation Challenges in the Medical Device Sector
Avanos Medical (AVNS) is positioned in the medical device industry with a focus on digestive health and non-opioid pain management. While the company faces profitability challenges, evidenced by a negative EPS and ROE, it shows operational efficiency with positive free cash flow and modest revenue growth. Investors looking at AVNS should consider its strategic innovation and long-term growth potential despite current valuation hurdles, especially within the healthcare sector's demand for advanced medical devices.
A Look At Siemens Healthineers (XTRA:SHL) Valuation After New Avanos Co‑Marketing Agreement
Siemens Healthineers recently announced a co-marketing agreement with Avanos Medical, pairing its imaging systems with radiofrequency ablation tools, following plans for disciplined acquisitions. Despite a 17.45% decline in shareholder return over the past year, the company is considered 21.5% undervalued, with a fair value estimate of €56.16 against its last close of €44.11. This valuation is supported by anticipated higher margin software and solutions revenues from digital and AI adoption and its installed diagnostic platforms.
New Avanos–Siemens alliance targets smoother outpatient pain procedures
Avanos Medical and Siemens Healthineers have announced a co-marketing agreement to integrate Avanos' radiofrequency ablation (RFA) technologies with Siemens' mobile C-arm imaging systems. This collaboration aims to enhance accuracy, efficiency, and consistency in outpatient and interventional pain management in the U.S. The partnership will focus on joint education, sales training, and marketing to promote a streamlined workflow for ambulatory surgery centers, hospitals, and pain practices.
Avanos Medical and Siemens Healthineers partner on pain management tech By Investing.com
Avanos Medical and Siemens Healthineers have formed a strategic co-marketing agreement to integrate Avanos' radiofrequency ablation technologies with Siemens Healthineers' imaging systems. This partnership aims to enhance pain management solutions for outpatient settings, focusing initially on the U.S. market. The collaboration follows Avanos Medical's strong Q3 2025 earnings, which exceeded analyst expectations.
Is Siemens Healthineers’ Avanos Pain-Care Tie-Up Reshaping the Investment Case for (XTRA:SHL)?
Siemens Healthineers and Avanos Medical have formed a co-marketing agreement in the U.S. to integrate imaging and radiofrequency ablation technologies for outpatient pain care. This collaboration aims to enhance Siemens Healthineers' role in outpatient services and streamline pain procedures, aligning with its focus on incremental acquisitions and ecosystem development. While this move supports recurring revenues, investors should be mindful of ongoing Diagnostics restructuring and potential impacts from China's pricing reforms.
Avanos Medical and Siemens Healthineers Collaborate to Advance Integrated Solutions for Outpatient and Interventional Pain Management
Avanos Medical and Siemens Healthineers have announced a strategic co-marketing agreement to enhance outpatient and interventional pain care. This collaboration will integrate Avanos' radiofrequency ablation (RFA) technologies with Siemens Healthineers' mobile C-arm imaging systems. The partnership aims to provide ASCs, hospitals, and interventional pain practices with comprehensive, cost-effective solutions that improve workflow, clinical outcomes, and access to advanced pain management.
Avanos and Siemens Healthineers partner for integrated patient care solutions
Avanos Medical and Siemens Healthineers have formed a co-marketing agreement to enhance outpatient and interventional pain care. This partnership will integrate imaging and radiofrequency ablation (RFA) technologies, initially focusing on the U.S. market. The collaboration aims to improve accuracy, efficiency, and consistency in patient care by combining Siemens Healthineers' mobile C-arm systems with Avanos' technologies.
Avanos Medical, Inc. (AVNS): A Bull Case Theory
This article summarizes a bullish thesis on Avanos Medical, Inc. (AVNS), highlighting its position as a steady healthcare compounder in pain management and enteral feeding. The company benefits from high barriers to entry, predictable cash flows, and regulatory stability, with products like Coolief and On-Q pain pumps deeply integrated into hospital protocols. Macro trends like aging populations and the shift to non-opioid pain solutions further support its growth, positioning AVNS as a reliable low-beta franchise.
Avanos Medical, Inc. Presents at JP Morgan Healthcare Conference
Avanos Medical, Inc. presented its strategic initiatives at the JP Morgan Healthcare Conference on January 13, 2026. CEO Dave Pacitti highlighted plans for growth including expanding its global direct sales organization, leveraging a strong M&A pipeline, and mitigating tariff headwinds. The company projects net sales of $690-$700M with mid-single-digit growth.
Avanos Medical, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Avanos Medical, Inc. (NYSE: AVNS) announced that CEO Dave Pacitti will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at approximately 2:15 p.m. PST. A webcast of the presentation will be available on the Investors section of the company's website. Avanos Medical is a medical technology company focused on delivering clinically superior medical device solutions to help patients recover.
Does Avanos Medical (NYSE:AVNS) Have A Healthy Balance Sheet?
Avanos Medical has a manageable debt load with net debt of US$32.3m and good interest cover. Although its EBIT has declined, the company demonstrates strong free cash flow conversion, which helps service its debt comfortably. Shareholders should continue to monitor the balance sheet, but the overall assessment suggests the company can handle its current debt.
Does Avanos Medical (NYSE:AVNS) Have A Healthy Balance Sheet?
Avanos Medical (NYSE:AVNS) has reduced its debt to US$102.8m, with a net debt of US$32.3m after accounting for cash. While the company has liabilities exceeding its cash and near-term receivables, its market capitalization suggests these are manageable. Avanos Medical's strong conversion of EBIT to free cash flow indicates it can comfortably handle its debt despite a recent decline in EBIT.
Avanos Medical CEO to Present at J.P. Morgan Healthcare Conference on January 13
Avanos Medical CEO, Dave Pacitti, will present at the J.P. Morgan Healthcare Conference on January 13 in San Francisco, highlighting the company's latest medical technology advancements. The presentation will be webcast live and archived on Avanos Medical's investor website, ensuring transparency for investors. Avanos Medical, a medical technology company, focuses on developing solutions for nutritional support and opioid reduction, holding leading market positions globally.
Avanos Medical, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Avanos Medical, Inc. (NYSE: AVNS) announced that CEO Dave Pacitti will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13th at approximately 2:15 p.m. PST. A webcast of the presentation will be available on the Investors section of the company's website. Avanos Medical is a medical technology company focused on delivering superior medical device solutions to improve patient care.
Avanos Medical: Quiet Chart, Loud Questions as Wall Street Weighs the Next Move
Avanos Medical's stock has shown quiet sideways movement, reflecting cautious investor sentiment amid restructuring and litigation concerns. While analysts largely hold a "Neutral" stance, the company needs to demonstrate margin improvement, resolve legal issues, and show sustained revenue growth to break out of its current holding pattern. Its future hinges on successful execution in these areas to become a steady compounder rather than a source of frustration.
Pacer Advisors Inc. Sells 148,738 Shares of Avanos Medical, Inc. $AVNS
Pacer Advisors Inc. reduced its stake in Avanos Medical by 31.1% in the third quarter, selling 148,738 shares and now holding 328,805 shares valued at $3.80 million. Despite beating quarterly earnings and revenue estimates, the company reported a negative net margin of 67% and analyst sentiment remains mixed-to-negative, with institutional investors owning 95.17% of the stock. Insiders have also been reducing their holdings.
Voya Investment Management LLC Sells 96,398 Shares of Avanos Medical, Inc. $AVNS
Voya Investment Management LLC significantly reduced its stake in Avanos Medical, Inc. (NYSE:AVNS) by 41.1%, selling 96,398 shares and retaining 138,233 shares valued at $1.598 million. Despite mixed analyst ratings generally leaning negative, Avanos Medical exceeded Q3 estimates with revenue of $177.8M and EPS of $0.22, guiding FY25 EPS to $0.85–$0.95, though the company currently maintains a negative net margin. Institutional investors and hedge funds collectively hold approximately 95.17% of the stock.
93,572 Shares in Avanos Medical, Inc. $AVNS Bought by Squarepoint Ops LLC
Squarepoint Ops LLC acquired a new stake in Avanos Medical, Inc. (NYSE:AVNS) by purchasing 93,572 shares valued at approximately $1.145 million in the second quarter. Despite this institutional investor activity, analyst sentiment towards Avanos Medical is mixed-to-negative, with an average "Sell" rating and concerns about the company's negative net margin and P/E ratio. An SVP also recently sold 15,000 shares, reducing their holding by over 15%.
Avanos Medical signals breakthrough with ESENTEC lesion shape offering 255 mm squared volume
Avanos Medical has introduced its ESENTEC elliptical lesion shape, featuring an average volume of 255 mm squared. This innovation is designed to improve procedures for pain management professionals and demonstrates Avanos Medical's dedication to developing innovative solutions in the medical device sector. The launch reflects the company's commitment to innovation and enhancing patient outcomes, as highlighted through initiatives like "Tubie Tales."
Avanos Medical Acquires Nexus Medical for Growth
Avanos Medical (NYSE:AVNS) has acquired Nexus Medical, a move expected to enhance its leadership in the infusion therapy market. This strategic acquisition aims to accelerate global expansion and broaden Avanos's portfolio with Nexus's innovative closed-system devices. The financial details of the acquisition were not disclosed initially.
Smart Enteral Feeding Pumps Market Size, Potential Scope 2033
The global Smart Enteral Feeding Pumps Market is projected to grow from USD 1.8 Billion in 2024 to USD 3.5 Billion by 2033, exhibiting an 8.2% CAGR from 2026 to 2033. This growth is driven by advancements in AI and machine learning, leading to adaptive feeding, predictive maintenance, and precision nutritional therapies, as well as increasing demand from homecare settings. Key players include Baxter, Nipro, B Braun, and Medtronic, navigating challenges like high costs and regulatory hurdles.
Brown Advisory Inc. Sells 122,328 Shares of Avanos Medical, Inc. $AVNS
Brown Advisory Inc. reduced its stake in Avanos Medical by 6.3%, selling over 122,000 shares, bringing its total ownership to about 3.90% valued at $22.14 million. This move comes despite Avanos Medical exceeding earnings and revenue expectations in its latest quarter, though the company still faces a negative P/E ratio and cautious analyst sentiment with a consensus "Sell" rating. Additionally, SVP Kerr Holbrook also sold 15,000 shares of the company's stock, further highlighting insider caution.
Why Is Avanos Medical (AVNS) Down 0.5% Since Last Earnings Report?
Avanos Medical (AVNS) has seen its shares drop 0.5% since its last earnings report, underperforming the S&P 500. Despite this, the company's Q3 2025 earnings beat estimates and it raised its full-year sales outlook. However, estimates for the stock have trended downward, leading to a Zacks Rank #4 (Sell).
Avanos Medical (NYSE:AVNS) Lowered to Strong Sell Rating by Zacks Research
Zacks Research has downgraded Avanos Medical (NYSE:AVNS) from a "hold" to a "strong sell" rating, providing multi-year EPS forecasts. Despite recently beating Q3 earnings estimates, the company reported a negative net margin of 67% and set a modest FY2025 EPS guidance. Institutional investors hold a significant portion of the shares, while an insider recently sold 15,000 shares.
Paradice Investment Management LLC Decreases Stake in Avanos Medical, Inc. $AVNS
Paradice Investment Management LLC reduced its stake in Avanos Medical, Inc. by 2.2% in the second quarter, now holding 1,257,824 shares valued at approximately $15.4 million. Despite the institutional selling and a "Reduce" consensus rating from analysts, Avanos Medical exceeded its quarterly earnings and revenue estimates. Insiders and other institutional investors have also adjusted their positions, and a SVP notably decreased their holdings recently.
Insider Sell Alert: Kerr Holbrook Sells 15,000 Shares of Avanos Medical Inc (AVNS)
Kerr Holbrook, Senior Vice President and Chief Commercial Officer at Avanos Medical Inc, sold 15,000 shares of the company on November 18, 2025. This transaction leaves him with 83,860 shares. Avanos Medical Inc is currently trading at $11 per share, which is significantly below its GF Value of $20.50, suggesting it may be a "Possible Value Trap."
Avanos Medical, Inc. (NYSE:AVNS) Q3 2025 Earnings Call Transcript
Avanos Medical, Inc. reported its Q3 2025 earnings, with net sales around $178 million and adjusted diluted EPS of $0.22, exceeding earnings expectations despite missing on the headline EPS. The company is actively pursuing strategic imperatives including accelerating growth in key segments, managing tariff impacts, and divesting underperforming assets, alongside acquiring synergistic businesses like Nexus Medical. Avanos has also raised its full-year revenue and adjusted EPS estimates due to strong sales momentum and effective cost discipline.
Nov. 5, 9 a.m. ET: Avanos Medical (NYSE: AVNS) to webcast financial results call
Avanos Medical (NYSE: AVNS) announced a conference call and webcast for Wednesday, November 5, 2025, at 9:00 AM ET, to discuss its third-quarter 2025 financial results and business highlights. The company will issue a news release with results before market open on the same day. Hosted by CEO Dave Pacitti and SVP & CFO Scott Galovan, investors can access the call via phone registration or a simultaneous webcast on the Avanos Investors website.
AVANOS MEDICAL, INC. SEC 10-K Report
Avanos Medical, Inc. released its 2024 10-K report detailing its financial performance, business operations, and strategic initiatives. The company reported a net loss of $(392.1) million driven by impairment charges, despite a 2.2% increase in net sales to $687.8 million. Avanos is undergoing a three-year transformation process, which includes divesting its Respiratory Health business and acquiring Diros Technology, Inc., to focus on core markets like Digestive Health and Pain Management and Recovery.
WRS Group Announces Agreement to Acquire Avanos Medical's US Game Ready® Orthopedic Rental Business
WRS Group has entered into a definitive agreement to acquire substantially all assets and rights related to Avanos Medical's US Game Ready® orthopedic rental business. This acquisition strengthens WRS's position in the US orthopedic market and enhances its ability to provide recovery solutions. Avanos Medical will continue to manufacture and supply Game Ready systems, focusing on its core growth platforms.
WRS Group Announces Agreement to Acquire Avanos Medical's US Game Ready® Orthopedic Rental Business
WRS Group, a national leader in orthopedic pain management, announced its agreement to acquire substantially all assets and rights related to Avanos Medical's US Game Ready® orthopedic rental business. This acquisition strengthens WRS's position in the US orthopedic market and allows Avanos to focus on its core growth platforms. The deal, effective December 1, 2025, also includes a long-term distribution and supply agreement, with Avanos continuing to manufacture and supply Game Ready systems.
Dimensional Fund Advisors LP Reduces Stake in Avanos Medical Inc - GuruFocus
Dimensional Fund Advisors LP reduced its stake in Avanos Medical Inc. by 8.74%, selling 225,430 shares, though Avanos Medical still accounts for a minor portion of the firm's portfolio. Avanos Medical, a medical device company, is noted for its mixed financial performance, including a significantly negative EBITDA growth and a stock price below its GF Value, indicating a potential value trap.
Behavioral Patterns of AVNS and Institutional Flows - news.stocktradersdaily.com
This article analyzes Avanos Medical Inc. (NASDAQ: AVNS) using AI models, indicating weak sentiment across all time horizons and supporting a short bias. It highlights a significant risk-reward short setup with a 14.0% downside target against a minimal risk. The article also presents institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Lobbying Update: $60,000 of AVANOS MEDICAL INC. (FKA HALYARD HEALTH INC.) lobbying was just disclosed
A recent Lobbying Disclosure Act filing revealed that AVANOS MEDICAL INC. (fka HALYARD HEALTH INC.) disclosed $60,000 in lobbying expenses for Q3 2025, addressing issues like proposed tariffs. The article also details insider trading activity, showing Gary Blackford's two purchases of 60,000 shares for an estimated $659,300, and significant hedge fund activity with 126 institutions adding and 99 decreasing their positions in AVNS stock.
Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio
Avanos Medical, Inc. has acquired Nexus Medical, LLC to enhance its critical care portfolio, specifically in nutrition and medication delivery. This acquisition strengthens Avanos' Specialty Nutrition Systems business by adding Nexus Medical’s TKO anti-reflux needleless connector technology, which is crucial for minimizing blood reflux and improving safety in settings like NICUs and PICUs. The transaction, financed by existing cash reserves, is expected to be immediately accretive to Avanos’ revenue growth and earnings per share, positioning the company for potential near-term stock upside.
Avanos Medical acquires Nexus Medical to enhance critical care solutions
Avanos Medical has acquired Nexus Medical, LLC, a medical device company specializing in TKO anti-reflux needleless connector technology for critical care settings. This strategic acquisition, funded by Avanos' cash reserves, is expected to immediately boost revenue and earnings per share. Nexus Medical's technology complements Avanos' existing Specialty Nutrition Systems business, enhancing its solutions for neonatal and pediatric patients.
Avanos Medical’s SWOT analysis: stock performance amid transition
Avanos Medical (NYSE:AVNS) is undergoing a significant transition marked by leadership changes and strategic realignments, including the divestiture of its Hyaluronic Acid product lines. Despite anticipated margin pressure from tariffs and a projected slight revenue decline for FY2025, the company has outperformed expectations in recent quarters, buoyed by strong growth in key segments like Radiofrequency Ablation. Analysts view 2025 as a transitional year, with the new CEO's experience and segment restructuring offering potential for future growth and improved operational efficiency.
Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down
Avanos Medical (AVNS) reported Q2 2025 adjusted earnings of 17 cents per share, missing estimates by 5.6% and down 50% year over year, while revenues rose 1.9% to $175 million, beating expectations. The company's shares dropped significantly following the mixed results, impacted by weakening margins and tariff-related manufacturing costs. Despite the mixed performance, Avanos reaffirmed its full-year 2025 outlook for net sales and adjusted EPS.
Avanos Q2 2025 slides: Revenue grows while profits decline, shares tumble
Avanos Medical Inc. (NYSE: AVNS) shares dropped over 12% after its Q2 2025 earnings report showed modest revenue growth but a significant decline in profitability, including a non-cash goodwill impairment charge of $77 million. Despite the profit fall, the company maintained its full-year guidance and highlighted a strong balance sheet. The stock plummeted near its 52-week low.
